Novartis ADR Aktie News

Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren's disease, the second most prevalent rheumatic autoimmune disease2, at a late-breaker presentation during the American College of Rheumatology Convergence congress1.

The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revolution higher. Equities continue to hit all-time highs even the government shut down has nearly hit the one month mark and trade tensions remain between China and the U.S.

Novartis AG (NYSE:NVS ) Q3 2025 Earnings Call October 28, 2025 9:00 AM EDT Company Participants Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Matthew Weston - UBS Investment Bank, Research Division Peter Verdult - BNP Paribas Exane, Research Division Steve Scala - TD Cowen, Resear...

Novartis stock fell early Tuesday after a mixed third-quarter report that included a sales decline for heart-failure drug Entresto.

Shares in Swiss drugmaker Novartis were seen down 3.3% in pre-market trade on Tuesday after the company reported third-quarter profitability below market expectations, even as higher sales from key medicines helped offset losses from expiring patents. On the Swiss Exchange, the share price of the drugmaker was down by 3.76%.

Swiss drugmaker Novartis is exploring options to add more medicines to its direct to patient platform that is expected to launch in the U.S. next month, CEO Vas Narasimhan told Reuters in an interview on Tuesday.

The Swiss drugmaker announced its biggest deal in a decade on Sunday, as its set to buy Avidity Biosciences for about $12 billion.  "We have adequate firepower to do deals like this and to bolster the growth profile of the company," the CEO told CNBC.

The drugmaker reported third-quarter profit of $3.93 billion after higher sales for key drugs allowed it to offset a hit from patent expirations.